home.aspx
 
EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...

Adents Prodigi

SHARESHARESHARE
Leverage the business potential of your serialization data: Adents Prodigi is the only software solution able to generate, exchange, manage, enrich, analyze and enhance your serialization data.
SHARESHARESHARE

RELATED NEWS


On Wednesday, U.S. regulators granted the immunotherapy a priority review in previously untreated patients with extensive-stage small cell lung cancer. The move sets up Tecentriq which regulators will evaluate alongside chemotherapy for a speedy trip down the regulatory pathway, with the FDA expected to hand down a decision by March 18.
If Tecentriq can snag an OK, it will be the first time in 20 years that extensive-stage SCLC patients have had a front-line option that “delivers a ...


READ MORE

When there’s only one proven therapy for a global pandemic that’s infected millions—and a limited initial supply—how exactly should officials distribute it? So far, the U.S. government hasn't figured it out, reports say. When Gilead Sciences scored its groundbreaking FDA emergency use authorization for COVID-19 therapy remdesivir, the company made the unusual move of handing distribution rights to the federal government. But the rollout has gotten off to a rocky start...
FIERCEPHARMA
READ MORE

The U.S. Food and Drug Administration today approved TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox. Though the World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980, there have been longstanding concerns that smallpox could be used as a bioweapon. “To address the risk of bioterrorism, Congress has taken steps to enable the development and approval of countermeasures to thwart pathogens that co...
U.S. FOOD AND DRUG ADMINISTRATION
READ MORE

NICE has published final draft guidance recommending regular NHS funding in England for Takeda’s Alunbrig (brigatinib), for ALK-positive advanced non-small cell lung cancer, in patients already treated with Pfizer’s Xalkori. The decision from the cost-effectiveness body follows an earlier draft appraisal that said the drug was not cost-effective in this use. A further price cut from the company and further clarifications about its economic model mean it is now recommended for routine...

READ MORE

Duchenne muscular dystrophy (DMD) is a devastating genetic disease that impairs cardiac and skeletal muscle development. People with DMD gradually lose ambulation in childhood, acquire respiratory and heart failure in young adulthood and succumb to the disease by their mid-thirties. Until recently, there has been no effective treatment for the characteristic muscle-wasting progression of this disease. Provisional FDA approval of the first DMD therapy (eteplirsen) and improved disease management ...
DRUG TARGET REVIEW
READ MORE

AbbVie and Roche just nabbed an FDA approval that spares certain relapsed leukemia patients chemotherapy and could be key to $3 billion in peak sales to boot. Their new blood cancer drug Venclexta, combined with oncology stalwart Rituxan, won a nod to treat chronic lymphocytic leukemia patients who’ve relapsed. The approval expands Venclexta’s reach considerably, because it applies to CLL patients with or without a genetic mutation known as the 17p deletion. Plus, it’s the firs...
FIERCEPHARMA
READ MORE

EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...